Otonomy shares plunged 50.1 percent at news that the company’s drug to treat Meniere’s disease failed to hit the primary endpoint in a Phase III trial.
Irvine, California-based Novus Therapeutics announced that the company’s Phase IIa clinical trial of OPO201 in acute otitis media, or inflammation of the middle ear, failed to meet the primary endpoint.
